Aortic valve replacement (AVR) is the standard treatment for patient with severe, symptomatic aortic stenosis. Transcatheter aortic valve implantation (TAVI) is the new standard of therapy for those patients that are unsuitable for open heart surgery. In patients considered to be high risk secondary to severe comorbidities, TAVI may be an acceptable alternative to AVR. Future applications of transcatheter heart valves include intermediate-risk patients and failed bioprosthetic valves.
ASJC Scopus subject areas